英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
rusg查看　rusg　在百度字典中的解释百度英翻中〔查看〕
rusg查看　rusg　在Google字典中的解释Google英翻中〔查看〕
rusg查看　rusg　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First . . .
    The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults
  • label - accessdata. fda. gov
    AMVUTTRA is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality,
  • Alnylam Announces FDA Approval of AMVUTTRA - Business Wire
    The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary
  • Home | AMVUTTRA® (vutrisiran)
    AMVUTTRA® (vutrisiran) is a prescription medicine given once every 3 months by a healthcare professional to treat the polyneuropathy caused by hATTR amyloidosis in adults
  • FDA Approves Amvuttra for ATTR-CM in Extended Label
    Alnylam Pharmaceuticals announced that the FDA has approved their supplemental new drug application (sNDA) for Amvuttra (vutrisiran), for the treatment of the transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults, according to a news release
  • Amvuttra approved in US to treat adults with ATTR-CM
    The U S Food and Drug Administration (FDA) has extended the approval of Amvuttra (vutrisiran) to adults with cardiomyopathy (heart damage) due to nonhereditary or hereditary transthyretin amyloidosis (ATTR-CM)
  • FDA approves vutrisiran to treat ATTR-CM
    Alnylam Pharmaceuticals has received U S Food and Drug Administration (FDA) approval for vutrisiran, a subcutaneous injection the company sells under the brand name Amvuttra, to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
  • FDA Approves Alnylams Amvuttra® for Rare Disease
    This approval expands the indication for Amvuttra, making it the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults
  • Amvuttra: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (hATTR-PN) and cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) It is given as a subcutaneous injection every 3 months by a healthcare provider
  • Vutrisiran (AMVUTTRA) in Transthyretin Amyloid Cardiomyopathy (ATTR-CM . . .
    Reduced serum vitamin A levels: Vutrisiran causes a reduction in serum vitamin A levels Supplementation of the recommended daily allowance of vitamin A is advised with vutrisiran treatment Patients should be referred to an ophthalmologist if ocular symptoms of vitamin A deficiency occur





中文字典-英文字典  2005-2009